Massmutual Trust Co. FSB ADV Increases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Massmutual Trust Co. FSB ADV increased its position in Hologic, Inc. (NASDAQ:HOLX) by 20.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 831 shares of the medical equipment provider’s stock after buying an additional 140 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Hologic were worth $62,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ballentine Partners LLC acquired a new stake in Hologic in the 4th quarter valued at $262,000. Arizona State Retirement System lifted its position in Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock worth $4,810,000 after acquiring an additional 172 shares in the last quarter. Asset Management One Co. Ltd. boosted its holdings in Hologic by 2.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 99,725 shares of the medical equipment provider’s stock worth $7,106,000 after acquiring an additional 1,937 shares during the period. International Assets Investment Management LLC acquired a new stake in Hologic in the fourth quarter valued at approximately $950,000. Finally, Allworth Financial LP raised its stake in shares of Hologic by 39.3% during the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling

In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at $3,615,024. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Insiders have sold a total of 17,804 shares of company stock valued at $1,430,413 over the last quarter. Corporate insiders own 1.75% of the company’s stock.

Hologic Stock Performance

HOLX stock traded up $0.09 on Tuesday, reaching $82.45. The company’s stock had a trading volume of 1,781,384 shares, compared to its average volume of 1,649,319. The firm has a fifty day moving average of $75.51 and a two-hundred day moving average of $75.42. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.29. The company has a market capitalization of $19.15 billion, a P/E ratio of 42.64, a price-to-earnings-growth ratio of 2.64 and a beta of 0.99. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.15.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the firm posted $0.93 EPS. Hologic’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on HOLX shares. JPMorgan Chase & Co. upped their target price on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, July 30th. StockNews.com raised shares of Hologic from a “buy” rating to a “strong-buy” rating in a report on Friday. Stephens reaffirmed an “overweight” rating and set a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Finally, Royal Bank of Canada raised their price objective on Hologic from $81.00 to $82.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.